1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Episurf Medical AB Class B

Episurf Medical AB Class B

0.06
SEK
+0.00
(+1.94%)
-0.11EPS
589.12MMarket Cap
Nov 20Next Earn
Episurf Medical AB Class B
STO:EPIS_B
(Nasdaq Stockholm)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
- -
- -
- -
- -
- -
0.03
0.05
0.04
0.06
0.04
0.02
0.02
0.01
0.02
0.03
0.01
0.01
Revenue per Share
-0.27
-0.38
-0.61
-0.65
-0.92
-1.09
-1.32
-0.89
-0.9
-0.54
-0.21
-0.16
-0.15
-0.21
-0.16
-0.06
-0.11
Basic EPS, GAAP
-0.48
-0.42
-0.64
-0.69
-0.97
-1.13
-1.32
-1
-0.97
-0.5
-0.19
-0.15
-0.16
-0.2
-0.16
-0.06
0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.59
1.58
0.95
2.18
1.15
2.25
1
1.2
0.6
0.24
0.4
0.5
0.35
0.17
0.09
0.03
0.09
Book Value per Share
0.37
1.52
0.85
2.04
0.98
2.03
0.74
0.97
0.32
0.12
0.35
0.45
0.29
0.1
0.05
0.01
0.07
Tangible Book Value per Share
10
25
26
35
36
40
47
69
64
128
308
431
507
461
479
987
2,287
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
2
3
4
5
5
7
7
10
13
14
21
Sales/Revenue/Turnover
- -
- -
- -
-61,398.03
-19,223.27
-4,329.58
-2,565.2
-2,448
-1,437.5
-1,404.08
-1,268
-1,067.69
-1,166.67
-939.81
-593.85
-428.15
-287.74
Operating Margin (%)
- -
- -
1
1
2
2
4
4
5
7
8
7
7
9
9
8
- -
Depreciation Expense
-3
-10
-16
-23
-33
-44
-62
-61
-58
-70
-64
-69
-77
-95
-76
-58
-246
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-60,282.45
-19,022.82
-4,326.25
-2,563.48
-2,444
-1,445
-1,424.49
-1,278
-1,066.15
-1,171.21
-920.39
-584.62
-431.11
-1,160.38
Profit Margin (%)
6
38
22
66
33
98
36
69
24
18
146
230
146
48
46
7
238
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
2
1
4
2
- -
2
623
LT Debt
10
40
24
72
39
110
49
86
45
41
170
253
178
85
84
48
599
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-53.09
-38.62
-48.86
-47.62
-59.59
-59.11
-77.75
-90.99
-88.65
-161.95
-60.6
-32.82
-35.91
-72.31
-90.31
-88.65
-73.86
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3
3
3
LT Borrowings
- -
- -
622
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,660
2,810
6,931
Market Capitalization
62
161
589

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
18
42
401
Cash, Cash Equivalents & STI
7
12
363
Accounts Receivable, Net
5
7
- -
Inventories
3
3
- -
Total Current Liabilities
10
122
164
Payables & Accruals
- -
- -
- -
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.71%
-15.43%
-43.32%
Free Cash Flow
4.63%
2.75%
-21.52%
Net Income, GAAP
4.56%
-0.12%
-23.42%
Sales/Revenue/Turnover
34.28%
23.53%
3.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
3
3
3
13
2025
- -
2
- -
4
14
2026
3
12
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
-0.05
-0.02
-0.03
-0.16
2025
- -
- -
- -
-0.01
-0.06
2026
-0.01
-0.04
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Episurf Medical AB (publ) (Nasdaq Stockholm: EPIS B) develops, manufactures and commercializes patient-specific orthopedic implants and surgical instruments for minimally invasive treatment of joint injuries, targeting middle-aged patients with aging but not end-stage joints; core products include the Episealer Knee system for focal cartilage and bone defects in the knee, Episealer Talus for ankle lesions, Episealer Patellofemoral System for patellofemoral osteoarthritis, Episealer MTP implant for big toe joint injuries under FDA 510(k) review, Epioscopy for 3D lesion visualization, Epiguide surgical drill guides and the µiFidelity web platform for personalized design, pre-planning and order management. Founded in 2008 by Professor Leif Ryd and headquartered at Karlavägen 60 in Stockholm, Sweden, the company operates globally with sales representation in the United States, Europe and Asia, serving surgeons and healthcare institutions through a distributor-based model featuring exclusive partnerships with DePuy Synthes in the US and Joint Operations in Germany, Austria, the UK and Ireland since February 2025. Recent developments encompass a fully guaranteed rights issue of units in August 2025 raising up to SEK 29.4 million before costs to fund FDA clearance for Episealer MTP, US commercialization preparations and sales expansion of the Patellofemoral System and other products; a second cost-saving program announced in July 2025 targeting SEK 20 million in reductions following a prior 2024 initiative; transition to accelerated growth via distributor networks; change of liquidity provider to Mangold effective August 29, 2025; and publication of the 2024 annual report in April 2025.